CytomX Therapeutics (CTMX) Shares Outstanding (Diluted Average) (2019 - 2023)

CytomX Therapeutics has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $73.8 million in Q4 2023.

• For the quarter ending Q4 2023, Shares Outstanding (Diluted Average) rose 12.27% year-over-year to $73.8 million; the trailing twelve-month figure through Dec 2023 stood at $73.8 million (up 12.27% YoY), and the FY2023 full-year result was $73.8 million, up 12.27% from the prior year.
• Shares Outstanding (Diluted Average) for Q4 2023 stood at $73.8 million, up from $66.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $73.8 million in Q4 2023, with the low at $45.3 million in Q4 2019.
• Historically, Shares Outstanding (Diluted Average) has averaged $59.8 million across 5 years, with a median of $65.3 million in 2021.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Diluted Average) soared 41.25% — and 2022, when it advanced 0.68%.
• CytomX Therapeutics' Shares Outstanding (Diluted Average) stood at $45.3 million in 2019, then rose by 2.79% to $46.6 million in 2020, then soared by 40.12% to $65.3 million in 2021, then rose by 0.68% to $65.7 million in 2022, then rose by 12.27% to $73.8 million in 2023.
• The last three Shares Outstanding (Diluted Average) figures came in at $73.8 million (Q4 2023), $66.5 million (Q2 2023), and $66.2 million (Q1 2023), per Business Quant data.